165 related articles for article (PubMed ID: 16629862)
1. Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain.
Andresen V; Camilleri M
Neurogastroenterol Motil; 2006 May; 18(5):354-60. PubMed ID: 16629862
[TBL] [Abstract][Full Text] [Related]
2. Challenges in drug development for functional gastrointestinal disorders. Part I: functional dyspepsia.
Andresen V; Camilleri M
Neurogastroenterol Motil; 2006 May; 18(5):346-53. PubMed ID: 16629861
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders.
Camilleri M; Bueno L; de Ponti F; Fioramonti J; Lydiard RB; Tack J
Gastroenterology; 2006 Apr; 130(5):1421-34. PubMed ID: 16678556
[TBL] [Abstract][Full Text] [Related]
4. Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence.
Kuiken SD; Tytgat GN; Boeckxstaens GE
Aliment Pharmacol Ther; 2005 Mar; 21(6):633-51. PubMed ID: 15771750
[TBL] [Abstract][Full Text] [Related]
5. The trials and tribulations of drug development for functional gastrointestinal disorders.
Chang L
Neurogastroenterol Motil; 2008 May; 20 Suppl 1():130-8. PubMed ID: 18402650
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiology and clinical phenomenology of visceral pain].
Gschossmann JM; Holtmann G; Mayer EA
Schmerz; 2002 Dec; 16(6):447-51. PubMed ID: 12474030
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
Dobrek Ł; Thor PJ
Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders.
Faure C; Wieckowska A
J Pediatr; 2007 Jan; 150(1):66-71. PubMed ID: 17188617
[TBL] [Abstract][Full Text] [Related]
10. How to improve drug development for functional disorders.
Tack J; Corsetti M
Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):787-96. PubMed ID: 15324714
[TBL] [Abstract][Full Text] [Related]
11. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5.
Rösch W; Liebregts T; Gundermann KJ; Vinson B; Holtmann G
Phytomedicine; 2006; 13 Suppl 5():114-21. PubMed ID: 16978851
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
13. Predicting therapeutic efficacy - experimental pain in human subjects.
Chizh BA; Priestley T; Rowbotham M; Schaffler K
Brain Res Rev; 2009 Apr; 60(1):243-54. PubMed ID: 19168094
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology considerations in development of gastrohepatology products.
Lee SC; Apparaju S; Kim I; Estes K; Jappar D; Bashaw ED
Clin Pharmacol Ther; 2012 Sep; 92(3):281-3. PubMed ID: 22910484
[TBL] [Abstract][Full Text] [Related]
15. Human experimental pain models in drug development: translational pain research.
Arendt-Nielsen L; Curatolo M; Drewes A
Curr Opin Investig Drugs; 2007 Jan; 8(1):41-53. PubMed ID: 17263184
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.
Camilleri M; Talley NJ
Neurogastroenterol Motil; 2004 Apr; 16(2):135-42. PubMed ID: 15086867
[TBL] [Abstract][Full Text] [Related]
17. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
18. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.
Bueno L; de Ponti F; Fried M; Kullak-Ublick GA; Kwiatek MA; Pohl D; Quigley EM; Tack J; Talley NJ
Neurogastroenterol Motil; 2007 Jan; 19(1 Suppl):89-119. PubMed ID: 17280587
[TBL] [Abstract][Full Text] [Related]
19. 5-HT receptors and visceral hypersensitivity - 2B or not 2B, that is the question?
Grundy D
Neurogastroenterol Motil; 2006 May; 18(5):339-42. PubMed ID: 16629859
[No Abstract] [Full Text] [Related]
20. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
Boeckxstaens GE
Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
